Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAL-083 in MGMT Unmethylated Glioblastoma
NCT02717962Phase 2Completed
- Sponsor
- Kintara Therapeutics
- Start
- Jan 2017
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dianhydrogalactitol in glioblastoma (GBM) (2 arms), sponsored by Kintara Therapeutics. Primary endpoint: Overall Survival. Started Jan 2017; status: completed.
02
Drugs
dianhydrogalactitol
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02717962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02717962.